Vagistat-1 "broader spectrum" may be advantage over other treatments, BMS says.
This article was originally published in The Tan Sheet
BRISTOL-MYERS SQUIBB VAGISTAT-1 BROADER SPECTRUM is being highlighted by the company as one potential benefit of the new one-dose OTC vaginal yeast infection product. Speaking at a March 5 teleconference on the approval of the 6.5% tioconazole ointment, BMS Executive Medical Director Carole Sampson Landers, MD, said that in vitro, the product's active ingredient has "a little bit broader [spectrum] than some of the other azoles" on the market.
You may also be interested in...
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning